No change to Daiichi Sankyo's Ranbaxy plans
This article was originally published in Scrip
Executive Summary
If Daiichi Sankyowas having any reservations about its acquisition ofRanbaxy Laboratories, they were not in evidence at a briefing on company strategy in Tokyo, at which the Japanese firm again highlighted the benefits of the transaction.